Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579515 | 1.00 | MEN1 (0.42) | MEN1CYP2C9KMT2ADPP4AKR1C1 | |
| SCHEMBL11716598 | 1.00 | MEN1 (0.42) | MEN1CYP2C9KMT2ADPP4AKR1C1 | |
| Hydrochloric Acid SCHEMBL23579257 | 0.98 | MEN1 (0.41) | MEN1CYP2C9KMT2ADPP4AKR1C1 | |
| SCHEMBL23595545 | 0.81 | ALDH1A1 (0.38) | KMT2A | |
| SCHEMBL23595763 | 0.81 | SLC6A3 (0.43) | DPP4 | |
| SCHEMBL21452125 | 0.81 | SLC6A3 (0.43) | DPP4 | |
| SCHEMBL23595865 | 0.81 | SLC6A3 (0.43) | DPP4 | |
| SCHEMBL23579048 | 0.81 | ALDH1A1 (0.38) | KMT2A | |
| SCHEMBL23595854 | 0.81 | ALDH1A1 (0.38) | KMT2A | |
| SCHEMBL23595816 | 0.80 | KDM1A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| CN-115190815-B | Arylcyclohexylamine derivatives and their use in the treatment of psychotic disorders | 吉尔伽美什制药公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| CN-115190815-A | Arylcyclohexylamine derivatives and their use in the treatment of psychotic disorders | 吉尔伽美什制药公司 | 2022-10-14 | — | — | CN | disclosed |
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2021134086-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021134086-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | HTR2C, PNMT, HTR2A | MEN1 4659/4885CYP2C9 450/4885KMT2A 176/4885 |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | HTR2C, PNMT, HTR2A | MEN1 4745/4885CYP2C9 513/4885KMT2A 171/4885 |
| US-20240216339-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | HCRTR2, HCRTR1, HTR2A | MEN1 2040/4885CYP2C9 4112/4885KMT2A 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.